TRIM33 and dermatomyositis: None of the anti-TIF1γ autoantibody positive DM patients who were also positive for anti-Sp4 autoantibodies developed malignancy, as compared with 14% of the anti-Sp4 negative anti-TIF1γ autoantibody positive DM patients who developed CAM [8].